Arcus Biosciences Announces New Employment Inducement Grants

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Company’s Board of Directors granted seventeen new employees options to purchase a total of 559,000 shares of the Company’s common stock at an exercise price per share of $19.20, which was the closing price on October 8, 2020. The stock options were granted pursuant to the Com